{"doc_id": "33093056", "type of study": "Therapy", "title": "", "abstract": "Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial).\nTo investigate the effectiveness of using convalescent plasma to treat moderate coronavirus disease 2019 (covid-19) in adults in India.\nOpen label, parallel arm, phase II, multicentre, randomised controlled trial.\n39 public and private hospitals across India.\n464 adults (\u226518 years) admitted to hospital (screened 22 April to 14 July 2020) with confirmed moderate covid-19 (partial pressure of oxygen in arterial blood/fraction of inspired oxygen (PaO2/FiO2) ratio between 200 mm Hg and 300 mm Hg or a respiratory rate of more than 24/min with oxygen saturation 93% or less on room air): 235 were assigned to convalescent plasma with best standard of care (intervention arm) and 229 to best standard of care only (control arm).\nParticipants in the intervention arm received two doses of 200 mL convalescent plasma, transfused 24 hours apart.\nThe presence and levels of neutralising antibodies were not measured a priori; stored samples were assayed at the end of the study.\nMAIN OUTCOME MEASURE : Composite of progression to severe disease (PaO2/FiO2 <100 mm Hg) or all cause mortality at 28 days post-enrolment.\nProgression to severe disease or all cause mortality at 28 days after enrolment occurred in 44 (19%) participants in the intervention arm and 41 (18%) in the control arm (risk difference 0.008 (95% confidence interval -0.062 to 0.078); risk ratio 1.04, 95% confidence interval 0.71 to 1.54).\nConvalescent plasma was not associated with a reduction in progression to severe covid-19 or all cause mortality.\nThis trial has high generalisability and approximates convalescent plasma use in real life settings with limited laboratory capacity.\nA priori measurement of neutralising antibody titres in donors and participants might further clarify the role of convalescent plasma in the management of covid-19.\nTRIAL REGISTRATION : Clinical Trial Registry of India CTRI/2020/04/024775.\n\u00a9 Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC.\nNo commercial re-use. See rights and permissions.\nPublished by BMJ.\n", "Evidence Map": {"Enrollment": [{"term": "moderate covid-19", "negation": "affirmed", "UMLS": {}, "start": 41, "end": 58}, {"term": "adults", "negation": "affirmed", "UMLS": {}, "start": 62, "end": 68}, {"term": "moderate coronavirus disease 2019 ( covid-19 )", "negation": "affirmed", "UMLS": {}, "start": 71, "end": 117}, {"term": "adults", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 10}, {"term": "admitted to hospital", "negation": "affirmed", "UMLS": {}, "start": 25, "end": 45}, {"term": "moderate covid-19", "negation": "affirmed", "UMLS": {}, "start": 99, "end": 116}, {"term": "partial pressure of oxygen in", "negation": "affirmed", "UMLS": {}, "start": 119, "end": 148}, {"term": "fraction of inspired oxygen (", "negation": "affirmed", "UMLS": {}, "start": 166, "end": 195}, {"term": "FiO2 ) ratio", "negation": "affirmed", "UMLS": {}, "start": 203, "end": 215}, {"term": "200 mm Hg", "negation": "affirmed", "UMLS": {}, "start": 224, "end": 233}, {"term": "Hg", "negation": "affirmed", "UMLS": {}, "start": 231, "end": 233}, {"term": "respiratory rate of more than", "negation": "affirmed", "UMLS": {}, "start": 253, "end": 282}, {"term": "min with oxygen saturation 93 % or less on room air", "negation": "affirmed", "UMLS": {}, "start": 288, "end": 339}], "Comparison Results": [], "Study Arm 1 Results": [], "Study Arm 2 Results": [], "Hypothesis": []}, "Sentence-level breakdown": [{"Section": "TITLE", "Text": "Convalescent plasma in the management of moderate covid-19 in adults in India : open label phase II multicentre randomised controlled trial ( PLACID Trial ) .", "Evidence Elements": {"Participant": [{"term": "moderate covid-19", "negation": "affirmed", "UMLS": {}, "start": 41, "end": 58}, {"term": "adults", "negation": "affirmed", "UMLS": {}, "start": 62, "end": 68}], "Intervention": [{"term": "Convalescent plasma", "negation": "affirmed", "start": 0, "end": 19, "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "OBJECTIVE", "Text": "To investigate the effectiveness of using convalescent plasma to treat moderate coronavirus disease 2019 ( covid-19 ) in adults in India .", "Evidence Elements": {"Participant": [{"term": "moderate coronavirus disease 2019 ( covid-19 )", "negation": "affirmed", "UMLS": {}, "start": 71, "end": 117}], "Intervention": [{"term": "convalescent plasma", "negation": "affirmed", "start": 42, "end": 61, "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "DESIGN", "Text": "Open label , parallel arm , phase II , multicentre , randomised controlled trial .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "SETTING", "Text": "39 public and private hospitals across India .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "PARTICIPANTS", "Text": "464 adults ( \u226518 years ) admitted to hospital ( screened 22 April to 14 July 2020 ) with confirmed moderate covid-19 ( partial pressure of oxygen in arterial blood / fraction of inspired oxygen ( PaO2 / FiO2 ) ratio between 200 mm Hg and 300 mm Hg or a respiratory rate of more than 24 / min with oxygen saturation 93 % or less on room air ) : 235 were assigned to convalescent plasma with best standard of care ( intervention arm ) and 229 to best standard of care only ( control arm ) .", "Evidence Elements": {"Participant": [{"term": "adults", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 10}, {"term": "admitted to hospital", "negation": "affirmed", "UMLS": {}, "start": 25, "end": 45}, {"term": "moderate covid-19", "negation": "affirmed", "UMLS": {}, "start": 99, "end": 116}, {"term": "partial pressure of oxygen in", "negation": "affirmed", "UMLS": {}, "start": 119, "end": 148}, {"term": "fraction of inspired oxygen (", "negation": "affirmed", "UMLS": {}, "start": 166, "end": 195}, {"term": "FiO2 ) ratio", "negation": "affirmed", "UMLS": {}, "start": 203, "end": 215}, {"term": "200 mm Hg", "negation": "affirmed", "UMLS": {}, "start": 224, "end": 233}, {"term": "Hg", "negation": "affirmed", "UMLS": {}, "start": 231, "end": 233}, {"term": "respiratory rate of more than", "negation": "affirmed", "UMLS": {}, "start": 253, "end": 282}, {"term": "min with oxygen saturation 93 % or less on room air", "negation": "affirmed", "UMLS": {}, "start": 288, "end": 339}], "Intervention": [{"term": "convalescent plasma", "negation": "affirmed", "start": 365, "end": 384, "has_relation": "N/A"}, {"term": "best standard of care", "negation": "affirmed", "start": 390, "end": 411, "has_procedure": [{"text": "best standard of care", "maps_to": "C2936643:standard of care", "start": 0, "end": 21}], "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "INTERVENTIONS", "Text": "Participants in the intervention arm received two doses of 200 mL convalescent plasma , transfused 24 hours apart .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "intervention", "negation": "affirmed", "start": 20, "end": 32, "has_procedure": [{"text": "intervention", "maps_to": "C0886296:intervention", "start": 0, "end": 12}], "has_relation": "N/A"}, {"term": "two doses of 200 mL convalescent plasma", "negation": "affirmed", "start": 46, "end": 85, "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "INTERVENTIONS", "Text": "The presence and levels of neutralising antibodies were not measured apriori ; stored samples were assayed at the end of the study .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "presence and levels of neutralising antibodies", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 50}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "MAIN OUTCOME MEASURE : Composite of progression to severe disease ( PaO2 / FiO2 < 100 mm Hg ) or all cause mortality at 28 days post-enrolment .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "Composite of progression to severe disease", "negation": "affirmed", "UMLS": {}, "start": 23, "end": 65}, {"term": "all cause mortality", "negation": "affirmed", "UMLS": {}, "start": 97, "end": 116}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "Progression to severe disease or all cause mortality at 28 days after enrolment occurred in 44 ( 19 % ) participants in the intervention arm and 41 ( 18 % ) in the control arm ( risk difference 0.008 ( 95 % confidence interval -0.062 to 0.078 ) ; risk ratio 1.04 , 95 % confidence interval 0.71 to 1.54 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "intervention", "negation": "affirmed", "start": 124, "end": 136, "has_procedure": [{"text": "intervention", "maps_to": "C0886296:intervention", "start": 0, "end": 12}], "has_relation": "N/A"}, {"term": "control", "negation": "affirmed", "start": 164, "end": 171, "has_relation": "N/A"}], "Outcome": [{"term": "Progression to severe disease", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 29}, {"term": "all cause mortality", "negation": "affirmed", "UMLS": {}, "start": 33, "end": 52}, {"term": "risk", "negation": "affirmed", "UMLS": {}, "start": 178, "end": 182}], "Observation": [], "Count": [{"term": "44 ( 19 % ) participants", "negation": "affirmed", "UMLS": {}, "start": 92, "end": 116}, {"term": "41 ( 18 % )", "negation": "affirmed", "UMLS": {}, "start": 145, "end": 156}]}, "Evidence Propositions": [{"Intervention": "intervention", "Observation": "", "Count": "44 ( 19 % ) participants", "Outcome": "Progression to severe disease"}, {"Intervention": "intervention", "Observation": "", "Count": "44 ( 19 % ) participants", "Outcome": "all cause mortality"}]}, {"Section": "CONCLUSION", "Text": "Convalescent plasma was not associated with a reduction in progression to severe covid-19 or all cause mortality .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "Convalescent plasma", "negation": "affirmed", "start": 0, "end": 19, "has_relation": "N/A"}], "Outcome": [{"term": "progression to severe covid-19", "negation": "negated", "UMLS": {}, "start": 59, "end": 89}, {"term": "all cause mortality", "negation": "negated", "UMLS": {}, "start": 93, "end": 112}], "Observation": [{"term": "reduction", "negation": "negated", "UMLS": {}, "start": 46, "end": 55}], "Count": []}, "Evidence Propositions": [{"Intervention": "Convalescent plasma", "Observation": "reduction", "Outcome": "progression to severe covid-19", "Count": ""}, {"Intervention": "Convalescent plasma", "Observation": "reduction", "Outcome": "all cause mortality", "Count": ""}]}, {"Section": "CONCLUSION", "Text": "This trial has high generalisability and approximates convalescent plasma use in real life settings with limited laboratory capacity .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [{"term": "high", "negation": "affirmed", "UMLS": {}, "start": 15, "end": 19}], "Count": []}, "Evidence Propositions": []}, {"Section": "CONCLUSION", "Text": "Apriori measurement of neutralising antibody titres in donors and participants might further clarify the role of convalescent plasma in the management of covid-19 .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "TRIAL REGISTRATION : Clinical Trial Registry of India CTRI / 2020 / 04 / 024775 .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "\u00a9 Author (s ) ( or their employer (s ) ) 2019 . Re-use permitted under CC BY-NC .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "No commercial re-use . See rights and permissions .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Published by BMJ .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}]}